The stock of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) decreased by -$2.32 on Tuesday to finish at $40.65, down -5.40 percent. The last five days have seen an average of 5,218,420 shares of common stock traded. 22 times new highs were reached in the current year, with a fall of -$11.06. The average number of shares traded over the last 20 days was 5,527,215, while the average volume over the last 50 days totaled 5,605,674.
APLS stock appreciated 57.86% since last month. On 08/07/23, the company’s shares reached a one-month low of $19.83. The stock touched a high of $94.75 on 06/14/23, after rallying from a low of $19.83 in 52 weeks. The price of APLS stock has declined by -21.39% or -$11.06 this year, reaching a new high 22 times. Still, the stock price is down -57.10% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
APLS stock investors should be aware that Apellis Pharmaceuticals Inc. (APLS) stock had its last reported insider trading activity 22 days ago on Aug 08. On Aug 08, Chief Scientific Officer Deschatelets Pascal sold 12,000 shares at $23.66 each. This transaction resulted in the insider making $283,920. On Jul 17, Machiels Alec sold 1,250 shares at a price of US$64.79. After the transaction, the insider now owns 267,641 shares. Chief Scientific Officer Deschatelets Pascal had earlier sold 12,000 shares on Jul 10 for $84.55 a share. The transaction was completed for $1,014,600.
Valuation Metrics
Beta for the stock is 1.00. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 25.50, the price-to-book (PB) ratio of 14.07.
Financial Health
For the three months ended June 29, Apellis Pharmaceuticals Inc.’s quick ratio was 4.50, while its current ratio was 5.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.11, and the total debt to equity ratio is 1.24. As far as profitability goes, gross margin for the trailing twelve months is 88.90% percent. Based on annual data, it had gross profit of $69.79 million and revenue of $75.42 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. APLS’s return on assets (ROA) during the last 12 months has been -74.50%. There was a -103.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -212.80%.
Earnings Surprise
According to Apellis Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $94.97 million, while revenues rose by 82.82% to $44.85 million. It was predicted that Apellis Pharmaceuticals Inc.’s quarterly earnings would be -$1.02, but it ended up being -$1.32, beating the consensus by 22.70%. EBITDA was -$106.88 million for the quarter. At the end of Apellis Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 570.17 million, while its total debt was $110.8 million. Equity owned by shareholders amounts to $117.74 million.
Technical Picture
Here’s a quick look at Apellis Pharmaceuticals Inc.’s (APLS) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 63.89%, suggesting the stock is Neutral, with a 137.25% historical volatility rate.
The stochastic %K and %D were 90.84% and 89.80% respectively, while the average true range (ATR) was 3.40. Based on the 14-day stochastic reading of 86.10%, the RSI (14) reading is 53.49%. On the 9-day MACD Oscillator, the stock is at 4.99, and the 14-day reading is at 6.78.
Analyst Ratings
In a note to investors, Citigroup maintained its a Buy rating on Apellis Pharmaceuticals Inc. (NASDAQ: APLS). However, the firm raised their price target to $54, indicating a possible increase of 9.67% in the stock price. Analysts have assigned Apellis Pharmaceuticals Inc. (APLS) an Overweight rating. APLS is a stock that is recommended for selling by 0 brokerage firms, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 9 others recommend it as a buy.
What is APLS’s price target for the next 12 months?
The current consensus forecast for the stock is between $29.00 and $95.00, with a median target price of $64.50. In analyzing these forecasts, the average price target given by analysts for Apellis Pharmaceuticals Inc. (APLS) is $64.64.
